The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Quetiapine versus other atypical antipsychotics for schizophrenia
Open accessAbstract
BACKGROUND: In many countries of the industrialised world second generation ('atypical') antipsychotic drugs have become the first line drug treatment for people with schizophrenia. It is not clear how the effects of the various second generation antipsychotic drugs differ. OBJECTIVES: To evaluate the effects of quetiapine compared with other second generation antipsychotic drugs for people with schizophrenia and schizophrenia-like psychosis. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group Trials Register (April 2007), inspected references of all identified studies, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised control trials comparing oral quetiapine with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated weighted mean differences (WMD) again based on a random-effects model. MAIN RESULTS: The review currently includes 21 randomised control trials (RCTs) with 4101 participants. These trials provided data on four comparisons - quetiapine versus clozapine, olanzapine, risperidone or ziprasidone.A major limitation to all findings is the high number of participants leaving studies prematurely (57.6%) and the substantial risk of biases in studies. Efficacy data favoured olanzapine and risperidone compared with quetiapine (PANSS total score versus olanzapine:10 RCTs, n=1449, WMD 3.66 CI 1.93 to 5.39; versus risperidone: 9 RCTs, n=1953, WMD 3.09 CI 1.01 to 5.16), but clinical meaning is unclear. There were no clear mental state differences when quetiapine was compared with clozapine or ziprasidone.Compared with olanzapine, quetiapine produced slightly fewer movement disorders (6 RCTs, n=1090, RR use of antiparkinson medication 0.49 CI 0.3 to 0.79, NNH 25 CI 14 to 100) and less weight gain (7 RCTs, n=1173, WMD -2.81 CI -4.38 to -1.24) and glucose elevation, but more QTc prolongation (3 RCTs, n=643, WMD 4.81 CI 0.34 to 9.28). Compared with risperidone, quetiapine induced slightly fewer movement disorders (6 RCTs, n=1715, RR use of antiparkinson medication 0.5 CI 0.3 to 0.86, NNH 20 CI 10 to 100), less prolactin increase (6 RCTs, n=1731, WMD -35.28 CI -44.36 to -26.19) and some related adverse effects, but more cholesterol increase (5 RCTs, n=1433, WMD 8.61 CI 4.66 to 12.56). Compared with ziprasidone, quetiapine induced slightly fewer extrapyramidal adverse effects (1 RCT, n=522, RR use of antiparkinson medication 0.43 CI 0.2 to 0.93, NNH not estimable) and prolactin increase. On the other hand quetiapine was more sedating and led to more weight gain (2 RCTs, n=754, RR 2.22 CI 1.35 to 3.63, NNH 13 CI 8 to 33) and cholesterol increase than ziprasidone. AUTHORS' CONCLUSIONS: Best available evidence from trials suggests that most people who start quetiapine stop taking it within a few weeks. Comparisons with amisulpride, aripiprazole, sertindole and zotepine do not exist. Most data that has been reported within existing comparisons are of very limited value because of assumptions and biases within them. There is much scope for further research into the effects of this widely used drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Risperidone versus other atypical antipsychotic medication for schizophrenia
Gilbody, S. M., Bagnall, A., Duggan, L., & Tuunainen, A. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002306 · Cited by 43
RetractedDiagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,701
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.388 · Cited by 1,688
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations
Andreasen, N. C. (1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291496 · Cited by 1,530
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers
Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., Tunis, S., Bergel, E., Harvey, I., Magid, D. J., et al. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.12.011 · Cited by 1,389
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,348
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
LEUCHT, S., KANE, J., KISSLING, W., HAMANN, J., ETSCHEL, E., & ENGEL, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.008 · Cited by 1,226
Self-citationUkoumunne, Gulliford, Chinn, Sterne, & Burney (1999) · Health Technology Assessment · doi:10.3310/hta3050 · Cited by 1,210
Birchwood, M., Smith, J., Cochrane, R., Wetton, S., & Copestake, S. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.157.6.853 · Cited by 1,157
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Hogan, T. P., Awad, A. G., & Eastwood, R. (1983) · Psychological Medicine · doi:10.1017/s0033291700050182 · Cited by 1,028
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Marwaha, S., & Johnson, S. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-004-0762-4 · Cited by 922
Clinical implications of Brief Psychiatric Rating Scale scores
Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.4.366 · Cited by 896
Self-citationMueser, K. T., & McGurk, S. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16458-1 · Cited by 876
Marshall, M., Lockwood, A., Bradley, C., Adams, C., Joy, C., & Fenton, M. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.249 · Cited by 870
Chapter 12: Interpreting results and drawing conclusions
Schünemann, H. J., Oxman, A. D., Jonathan, J., & Glasziou, P. (2011) · Cited by 870
Gulliford, M. C., Ukoumunne, O. C., & Chinn, S. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009904 · Cited by 852
Bland, J. M., & Kerry, S. M. (1997) · BMJ · doi:10.1136/bmj.315.7108.600 · Cited by 754
The unit of analysis error in studies about physicians' patient care behavior
Divine, G. W., Brown, J. T., & Frazier, L. M. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599201 · Cited by 749
Issues in the meta-analysis of cluster randomized trials
Donner, A., & Klar, N. (2002) · Statistics in Medicine · doi:10.1002/sim.1301 · Cited by 734
Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology
TANDON, R., KESHAVAN, M., & NASRALLAH, H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.04.011 · Cited by 720
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Stroup, T. S., McEvoy, J. P., Swartz, M. S., Byerly, M. J., Glick, I. D., Canive, J. M., McGee, M. F., Simpson, G. M., Stevens, M. C., & Lieberman, J. A. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006986 · Cited by 636
Interpreting results and drawing conclusions
Schünemann, H. J., Vist, G. E., Higgins, J. P., Santesso, N., Deeks, J. J., Glasziou, P., Akl, E. A., Guyatt, G. H., & on behalf of the Cochrane GRADEing Methods Group (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch15 · Cited by 595
Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].
Boissel, J., Cucherat, M., Li, W., Châtellier, G., Gueyffier, F., Buyse, M. E., Boutitie, F., Nony, P., Haugh, M., & Mignot, G. (1999) · PubMed · Cited by 533
Carpenter, W. T., & Buchanan, R. W. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403103301006 · Cited by 510
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Self-citationLindenmayer, J.-P., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.290 · Cited by 465
Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., & Leucht, S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.185 · Cited by 450
Self-citationLewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377
Harrigan, E. P., Miceli, J. J., Anziano, R., Watsky, E., Reeves, K. R., Cutler, N. R., Sramek, J., Shiovitz, T., & Middle, M. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104913.75206.62 · Cited by 363
Krakowski, M. I., Czobor, P., Citrome, L., Bark, N., & Cooper, T. B. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.622 · Cited by 352
Treatment-Resistant Schizophrenia
Elkis, H. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.04.001 · Cited by 338
Clozapine versus typical neuroleptic medication for schizophrenia
Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059.pub2 · Cited by 329
Naber, D. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199509000-00017 · Cited by 309
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.611 · Cited by 306
Swartz, M. S., Perkins, D. O., Stroup, T. S., Davis, S. M., Capuano, G., Rosenheck, R. A., Reimherr, F., McGee, M. F., Keefe, R. S. E., McEvoy, J. P., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.428 · Cited by 291
Bondolfi, G., Dufour, H., Patris, M., May, J. P., Billeter, U., Eap, C. B., & Baumann, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.499 · Cited by 283
Keefe, R. S. E., Sweeney, J. A., Gu, H., Hamer, R. M., Perkins, D. O., McEvoy, J. P., & Lieberman, J. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1061 · Cited by 276
Seroquel: biochemical profile of a potential atypical antipsychotic
Saller, C. F., & Salama, A. I. (1993) · Psychopharmacology · doi:10.1007/bf02244923 · Cited by 269
Extrapyramidal side-effects of antipsychotics in a randomised trial
Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M. S., Keefe, R. S. E., et al. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.050088 · Cited by 265
Hutton, J. L. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07707.x · Cited by 260
Mohamed, S., Rosenheck, R., McEvoy, J., Swartz, M., Stroup, S., & Lieberman, J. A. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn067 · Cited by 258
Tsuang, M. T. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770260031002 · Cited by 252
Duggan, L., Fenton, M., Rathbone, J., Dardennes, R., El-Dosoky, A., & Indran, S. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001359.pub2 · Cited by 237
Agranulocytosis during treatment with clozapine
Id�np��n-Heikkil�, J., Alhava, E., Olkinuora, M., & Palva, I. P. (1977) · European Journal of Clinical Pharmacology · doi:10.1007/bf00606409 · Cited by 237
Lewis, S., Davies, L., Jones, P., Barnes, T., Murray, R., Kerwin, R., Taylor, D., Hayhurst, K., Markwick, A., Lloyd, H., et al. (2006) · Health Technology Assessment · doi:10.3310/hta10170 · Cited by 233
Does switching to a new antipsychotic improve outcomes?
Rosenheck, R. A., Davis, S., Covell, N., Essock, S., Swartz, M., Stroup, S., McEvoy, J., & Lieberman, J. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.031 · Cited by 232
Aripiprazole for schizophrenia
El-Sayeh, H. G., & Morganti, C. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004578.pub3 · Cited by 230
Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison
Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., Tossell, J. W., Lenane, M., & Rapoport, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.721 · Cited by 225
Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.006 · Cited by 223
Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H. M., DeThomas, C., Kafantaris, V., Correll, C. U., & Kane, J. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.043 · Cited by 223
Perkins, D. O., Gu, H., Weiden, P. J., McEvoy, J. P., Hamer, R. M., & Lieberman, J. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0114 · Cited by 221
Meyer, J. M., Nasrallah, H. A., McEvoy, J. P., Goff, D. C., Davis, S. M., Chakos, M., Patel, J. K., Keefe, R. S. E., Stroup, T. S., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.015 · Cited by 210
Breier, A. F., Malhotra, A. K., Su, T.-P., Pinals, D. A., Elman, I., Adler, C. M., Lafargue, R. T., Clifton, A., & Pickar, D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.294 · Cited by 208
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
Swanson, J. W., Swartz, M. S., Van Dorn, R. A., Volavka, J., Monahan, J., Stroup, T. S., McEvoy, J. P., Wagner, H. R., Elbogen, E. B., & Lieberman, J. A. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.042630 · Cited by 205
Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia
Mohamed, S., Rosenheck, R., Swartz, M., Stroup, S., Lieberman, J. A., & Keefe, R. S. E. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111713 · Cited by 203
Tollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202
Volavka, J., Czobor, P., Cooper, T. B., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., & Lieberman, J. A. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0109 · Cited by 201
Citrome, L., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., McEvoy, J., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.11.1510 · Cited by 200
Delorme, R., Bille, A., Betancur, C., Mathieu, F., Chabane, N., Mouren-Simeoni, M. C., & Leboyer, M. (2006) · BMC Psychiatry · doi:10.1186/1471-244x-6-1 · Cited by 197
Volavka, J., Czobor, P., Nolan, K., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., & Lieberman, J. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117424.05703.29 · Cited by 190
Elevation of Prolactin Levels by Atypical Antipsychotics
Turrone, P., Kapur, S., Seeman, M. V., & Flint, A. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.133 · Cited by 190
Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association
Czobor, P., Volavka, J., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00003 · Cited by 185
Risperidone versus typical antipsychotic medication for schizophrenia
Hunter, R., Kennedy, E., Song, F., Gadon, L., & Irving, C. B. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000440 · Cited by 183
Serum Leptin and Triglyceride Levels in Patients on Treatment With Atypical Antipsychotics
Atmaca, M., Kuloglu, M., Tezcan, E., & Ustundag, B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0516 · Cited by 181
Azorin, J.-M., Spiegel, R., Remington, G., Vanelle, J.-M., Péré, J.-J., Giguere, M., & Bourdeix, I. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1305 · Cited by 179
Gallhofer, B., Bauer, U., Lis, S., Krieger, S., & Gruppe, H. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)00010-7 · Cited by 177
Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial
Swartz, M. S., Stroup, T. S., McEvoy, J. P., Thomas, S., Rosenheck, R. A., Keefe, R. S. E., Hsiao, J., & Lieberman, J. A. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.5.500 · Cited by 172
Clozapine and Risperidone Treatment of Psychosis in Parkinson's Disease
Ellis, T. D., Cudkowicz, M., Sexton, P., & Growdon, J. H. (2000) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12.3.364 · Cited by 172
Harvey, P. D., Patterson, T. L., Potter, L. S., Zhong, K., & Brecher, M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1918 · Cited by 170
Patel, J. K., Buckley, P. F., Woolson, S., Hamer, R. M., McEvoy, J. P., Perkins, D. O., Lieberman, J. A., & for the CAFE investigators (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.025 · Cited by 169
Agelink, M. W., Majewski, T., Wurthmann, C., Lukas, K., Ullrich, H., Linka, T., & Klieser, E. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00003 · Cited by 166
Miller, D. D., McEvoy, J. P., Davis, S. M., Caroff, S. N., Saltz, B. L., Chakos, M. H., Swartz, M. S., Keefe, R. S. E., Rosenheck, R. A., Stroup, T. S., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.034 · Cited by 158
A Randomized Open-Label Study of the Impact of Quetiapine Versus Risperidone on Sexual Functioning
Knegtering, R., Castelein, S., Bous, H., van der Linde, J., Bruggeman, R., Kluiter, H., & van den Bosch, R. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106220.36344.04 · Cited by 147
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Bitter, I., Dossenbach, M. R. K., Brook, S., Feldman, P. D., Metcalfe, S., Gagiano, C. A., Füredi, J., Bartkó, G., Janka, Z., Bánki, C. M., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.033 · Cited by 147
Clozapine versus typical neuroleptic medication for schizophrenia
Wahlbeck, K., Cheine, M. V., & Essali, A. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059 · Cited by 144
Treatment of Suicidality in Schizophrenia
Meltzer, H. Y. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb05797.x · Cited by 143
Results of phase 3 of the CATIE schizophrenia trial
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Thomas, S., Swartz, M. S., Keefe, R. S. E., Miller, A. L., Rosenheck, R. A., & Hsiao, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.011 · Cited by 141
Mullen, J., Jibson, M. D., & Sweitzer, D. E. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)89080-3 · Cited by 141
Olanzapine and haloperidol in first episode psychosis: Two-year data
Green, A. I., Lieberman, J. A., Hamer, R. M., Glick, I. D., Gur, R. C., Kahn, R. S., McEvoy, J. P., Perkins, D. O., Rothschild, A. J., Sharma, T., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.021 · Cited by 134
Subjective well-being and quality of life under atypical antipsychotic treatment
Karow, A., & Naber, D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1052-z · Cited by 133
Elevated Prolactin in Pediatric Patients on Typical and Atypical Antipsychotics
Wudarsky, M., Nicolson, R., Hamburger, S. D., Spechler, L., Gochman, P., Bedwell, J. S., Lenane, M., & RAPOPORT, J. L. (1999) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1999.9.239 · Cited by 133
Boter, H., Peuskens, J., Libiger, J., Fleischhacker, W. W., Davidson, M., Galderisi, S., & Kahn, R. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.09.019 · Cited by 133
Bourgeois, M. L., Swendsen, J. D., Young, F. K., AMADOR, X. F., Pini, S., Cassano, G. B., Lindenmayer, J., Hsu, C., Alphs, L. D., Meltzer, H. Y., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1494 · Cited by 131
Trichard, C., Martinot, M. P., Attar-Levy, D., Recasens, C., Monnet, F. P., & Martinot, J. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.505 · Cited by 125
Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study
Galderisi, S., Davidson, M., Kahn, R. S., Mucci, A., Boter, H., Gheorghe, M., RYBAKOWSKI, J. K., Libiger, J., Dollfus, S., López-Ibor, J. J., et al. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.09.022 · Cited by 125
Srisurapanont, M., Maneeton, B., Maneeton, N., Lankappa, S. T., & Gandhi, R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000967.pub2 · Cited by 122
Self-citationValidation of Remission Criteria for Schizophrenia
van Os, J., Drukker, M., Campo, J. Á., Meijer, J. A. M. J., Bak, M., & Delespaul, P. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.2000 · Cited by 122
Klieser, E., Lehmann, E., Kinzler, E., Wurthmann, C., & HEINRICH, K. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00008 · Cited by 121
Ascher‐Svanum, H., Zhu, B., Faries, D. E., Landbloom, R. P., Swartz, M. S., & Swanson, J. W. (2006) · BMC Psychiatry · doi:10.1186/1471-244x-6-8 · Cited by 114
Seroquel: electrophysiological profile of a potential atypical antipsychotic
Goldstein, J. M., Litwin, L. C., Sutton, E. B., & Malick, J. B. (1993) · Psychopharmacology · doi:10.1007/bf02244924 · Cited by 114
Meyer, J. M., McEvoy, J. P., Davis, V. G., GOFF, D. C., Nasrallah, H. A., Thomas, S., Hsiao, J., Swartz, M. S., Stroup, T. S., & Lieberman, J. A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.06.005 · Cited by 113
Tandon, R., Marcus, R. N., Stock, E. G., Riera, L. C., Kostic, D., Pans, M., McQuade, R. D., Nyilas, M., Iwamoto, T., & CRANDALL, D. T. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2005.12.857 · Cited by 113
Meyer‐Lindenberg, A., Gruppe, H., Bauer, U., Lis, S., Krieger, S., & Gallhofer, B. (1997) · Pharmacopsychiatry · doi:10.1055/s-2007-979481 · Cited by 112
The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial
Fleischhacker, W. W., Keet, I. P. M., & Kahn, R. S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.06.004 · Cited by 110
Davies, L. M., Lewis, S. W., Jones, P. B., Barnes, T. R. E., Gaughran, F., Hayhurst, K. P., Markwick, A., & Lloyd, H. M. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.106.028654 · Cited by 109
Potkin, S. G., Alphs, L. D., Hsu, C., Krishnan, K., Anand, R., Young, F. K., Meltzer, H. Y., & Green, A. I. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00178-1 · Cited by 106
Potkin, S. G., Gharabawi, G. M., Greenspan, A. J., Mahmoud, R. A., Kosik‐Gonzalez, C., Rupnow, M. F. T., Bossie, C. A., Davidson, M., Burtea, V., ZHU, Y., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.027 · Cited by 102
Naber, D., Riedel, M. J., Klimke, A., Vorbach, E.-U., Lambert, M., Kühn, K. ‐., Bender, S., Bandelow, B., Lemmer, W., Moritz, S., et al. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00486.x · Cited by 102
Penn, D. L., Keefe, R. S. E., Thomas, S., Meyer-Kalos, P., Perkins, D. O., Losardo, D., & Lieberman, J. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.08.016 · Cited by 100
Dossenbach, M. R. K., Arango-Dávila, C. A., Ibarra, H. S., Landa, E., Aguilar, J., Caro, O., Leadbetter, J., & Assunção, S. S. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0810 · Cited by 93
Vaughan, K., McConaghy, N., Wolf, C., Myhr, C., & Black, T. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2000.00813.x · Cited by 91
Stroup, T. S., Appelbaum, P. S., Swartz, M. S., Patel, M. K. P. M. K., Thomas, S., Jeste, D. V., Kim, S. Y. H., Keefe, R. S. E., Manschreck, T. C., McEvoy, J. M., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.08.007 · Cited by 91
Naheed, M., & Green, B. (2001) · Current Medical Research and Opinion · doi:10.1185/0300799039117069 · Cited by 91
Conley, R. R., Kelly, D. L., Richardson, C. M., Tamminga, C. A., & Carpenter, W. T. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000096246.29231.73 · Cited by 90
The Effects of Clozapine and Risperidone on Spatial Working Memory in Schizophrenia
McGurk, S. R., Carter, C., GOLDMAN, R. S., Green, M. F., Marder, S. R., Xie, H., Schooler, N. R., & Kane, J. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.1013 · Cited by 89
Kelly, D. L., & Conley, R. R. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.08.010 · Cited by 88
Kelly, D. L., & Conley, R. R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0111 · Cited by 87
Canuso, C. M., Dirks, B., Carothers, J. L., Kosik‐Gonzalez, C., Bossie, C. A., Zhu, Y., Damaraju, C. V., Kalali, A. H., & Mahmoud, R. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08040613 · Cited by 86
Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis
Huber, T. J., Borsutzky, M., Schneider, U., & Emrich, H. M. (2004) · Acta Psychiatrica Scandinavica · doi:10.1046/j.1600-0447.2003.00251.x · Cited by 86
Newer atypical antipsychotic medication versus clozapine for schizophrenia
Tuunainen, A., & Wahlbeck, K. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000966 · Cited by 84
The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia.
Fleischhacker, W. W., Bergmann, K. J., Perovich, R., Pestreich, L. K., Borenstein, M., Lieberman, J. A., & Kane, J. M. (1989) · PubMed · Cited by 83
Kinon, B. J., Lipkovich, I. A., Edwards, S. B., Adams, D. H., Ascher‐Svanum, H., & Siris, S. G. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000204137.82298.06 · Cited by 83
Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia
Lindenmayer, J., Czobor, P., Volavka, J., Lieberman, J. A., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. B., & Chakos, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0416 · Cited by 81
Meyer, J. M., Davis, V. G., McEvoy, J. P., GOFF, D. C., Nasrallah, H. A., Thomas, S., Daumit, G. L., Hsiao, J., Swartz, M. S., Stroup, T. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.04.023 · Cited by 80
Do Clozapine and Risperidone Affect Social Competence and Problem Solving?
Bellack, A. S., Schooler, N. R., Marder, S. R., Kane, J. M., Brown, C. H., & Yang, Y. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.364 · Cited by 79
Olanzapine compared to quetiapine in adolescents with a first psychotic episode
Arango, C., Robles, O., Parellada, M., Fraguas, D., Ruíz-Sancho, A., Medina, Ó., Zabala, A., Bombín, I., & Moreno, D. M. (2009) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0749-5 · Cited by 78
Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study
Wahlbeck, K., Cheine, M. V., Tuisku, K., Ahokas, A., Joffe, G., & Rimón, R. (2000) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00118-4 · Cited by 76
Weickert, T. W., Goldberg, T. E., Marenco, S., Bigelow, L. B., Egan, M. F., & Weinberger, D. R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300216 · Cited by 76
Nolan, K. A., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., & Lieberman, J. A. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.04.010 · Cited by 76
Heinrich, K., Klieser, E., Lehmann, E., Kinzler, E., & Hruschka, H. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90029-9 · Cited by 74
Kinon, B. J., Noordsy, D. L., Liu‐Seifert, H., Gulliver, A. H., Ascher‐Svanum, H., & Kollack‐Walker, S. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000236658.16286.25 · Cited by 73
Gharabawi, G. M., Greenspan, A. J., Rupnow, M. F. T., Kosik‐Gonzalez, C., Bossie, C. A., Zhu, Y., Kalali, A. H., & Awad, A. G. (2006) · BMC Psychiatry · doi:10.1186/1471-244x-6-45 · Cited by 73
K�fferle, B., Tauscher, J. T., Asenbaum, S., Vesely, C., Podreka, I., Br�cke, T., & Kasper, S. F. (1997) · Psychopharmacology · doi:10.1007/s002130050409 · Cited by 68
Newcomer, J. W., Ratner, R. E., Eriksson, J. W., Emsley, R. A., Meulien, D., Miller, F., Leonova-Edlund, J., Leong, R. W., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04132 · Cited by 67
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
Kane, J. M., Khanna, S., Rajadhyaksha, S., & Giller, E. L. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182114.65134.81 · Cited by 65
Comparison of Quetiapine and Risperidone in the Treatment of Schizophrenia
Zhong, K., Sweitzer, D. E., Hamer, R. M., & Lieberman, J. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0712 · Cited by 65
Suicide and violent death among patients with schizophrenia
Allebeck, P., Varla, A., & Wistedt, B. (1986) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1986.tb06225.x · Cited by 65
Treatment programme and long‐term outcome in chronic schizophrenia
Kane, J. M. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05309.x · Cited by 64
Conley, R. R., Kelly, D. L., Nelson, M. W., Richardson, C. M., Feldman, S. M., Benham, R., Steiner, P., Yu, Y., Khan, I., McMullen, R., et al. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000172993.89879.0f · Cited by 64
Swartz, M. S., Wagner, H. R., Swanson, J. W., Stroup, T. S., McEvoy, J. P., Reimherr, F. W., Miller, D. D., McGee, M., Khan, A., Cañive, J. M., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.034 · Cited by 63
Bender, S., Dittmann-Balçar, A., Schall, U., Wolstein, J. R., Klimke, A., Riedel, M. J., Vorbach, E.-U., Kühn, K.-U., Lambert, M., Dittmann, R., et al. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005924 · Cited by 61
Metabolic Findings From the CATIE Trial and Their Relation to Tolerability
Nasrallah, H. A. (2006) · CNS Spectrums · doi:10.1017/s1092852900026663 · Cited by 59
Riedel, M. J., Müller, N., Strassnig, M., Spellmann, I., Engel, R. R., Musil, R., Dehning, S., Douhet, A., Schwarz, M., & Möller, H. ‐. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0622-6 · Cited by 59
Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia
Mori, K., Nagao, M., Yamashita, H., Morinobu, S., & Yamawaki, S. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.01.019 · Cited by 59
Carlson, C. D., Cavazzoni, P. A., Berg, P. H., et al. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0807 · Cited by 58
Goldberg, T. E., Dodge, M. R., Aloia, M. S., Egan, M. F., & Weinberger, D. R. (2000) · Psychological Medicine · doi:10.1017/s0033291799002639 · Cited by 58
Voruganti, L. P., AWAD, A., PARKER, G., Forrest, C. B., USMANI, Y., Fernando, M. L. D., & SENTHILAL, S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.002 · Cited by 57
Towards the improvement of compliance
Gäebel, W. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199702001-00006 · Cited by 56
Riedel, M. J., Müller, N., Spellmann, I., Engel, R. R., Musil, R., Valdevit, R., Dehning, S., Douhet, A., Cerovecki, A., Strassnig, M., et al. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0748-9 · Cited by 56
Assessment Issues and the Cost of Schizophrenia
Andreasen, N. C. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.3.475 · Cited by 56
Suicide and Schizophrenia: Clozapine and the InterSePT Study
Meltzer, H. Y. (1999) · The Journal of Clinical Psychiatry · Cited by 56
Swadi, H. S., Craig, B. J., Pirwani, N. Z., Black, V., Buchan, J. C., & Bobier, C. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283320511 · Cited by 54
Meltzer, H. Y., & Jayathilake, K. (1999) · PubMed · Cited by 53
Riedel, M. J., Spellmann, I., Strassnig, M., Douhet, A., Dehning, S., Opgen-Rhein, M., Valdevit, R., Engel, R. R., Kleindienst, N., Müller, N., et al. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0739-x · Cited by 53
Kelly, D. L., Conley, R. R., Richardson, C. M., Tamminga, C. A., & Carpenter, W. T. (2003) · Annals of Clinical Psychiatry · doi:10.1023/b:acli.0000008171.90644.f8 · Cited by 53
Glick, I. D., Zaninelli, R., Hsu, C., Young, F. K., Weiss, L., Günay, İ., & Kumar, V. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0513 · Cited by 52
Meltzer, H. Y. (1999) · PubMed · Cited by 51
Effectiveness of second-generation antipsychotics with acute-phase schizophrenia
Hatta, K., Sato, K., Hamakawa, H., Takebayashi, H., Kimura, N., Ochi, S., Sudo, Y., Asukai, N., Nakamura, H., Usui, C., et al. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.030 · Cited by 50
Reducing the Risk for Suicide in Schizophrenia and Affective Disorders
Meltzer, H. Y., & Baldessarini, R. J. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0920 · Cited by 48
Cortese, L., Caligiuri, M. P., Williams, R., Schieldrop, P., Manchanda, R., MALLA, A. K., & Harricharan, R. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318160864f · Cited by 47
Moresco, R. M., Cavallaro, R., Messa, C., Bravi, D., Gobbo, C. L., Galli, L., Lucignani, G., Colombo, C., Rizzo, G., Velonà, I., et al. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800306 · Cited by 46
Alphs, L. D., Anand, R., Islam, M., Meltzer, H. Y., Kane, J. M., Krishnan, R. R., Green, A. I., Potkin, S. G., Chouinard, G., Lindenmayer, J., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007102 · Cited by 43
Chouinard, G., Vainer, J. L., Bélanger, M., Turnier, L., Beaudry, P., Roy, J.-Y., & Miller, R. J. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90116-3 · Cited by 43
The impact of obesity on health care costs among persons with schizophrenia
Chwastiak, L., Rosenheck, R. A., McEvoy, J. P., Stroup, T. S., Swartz, M. S., Thomas, S., & Lieberman, J. A. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2008.09.012 · Cited by 41
Treatment-resistant schizophrenia: clinical experience with new antipsychotics
Bondolfi, G., Baumann, P., & Dufour, H. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)00012-0 · Cited by 39
Davies, L. M., Barnes, T. R. E., Jones, P. B., Lewis, S. W., Gaughran, F., Hayhurst, K. P., Markwick, A., & Lloyd, H. M. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00280.x · Cited by 39
Trait humor and longevity: Do comics have the last laugh?
Rotton, J. (1992) · Health Psychology · doi:10.1037//0278-6133.11.4.262 · Cited by 36
Scherer, H., Bédard, M., Stip, É., Paquet, F., Richer, F., Bériault, M., Rodriguez, J.-P., & Mottard, J. (2004) · Cognitive and Behavioral Neurology · doi:10.1097/00146965-200403000-00004 · Cited by 35
Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals
Hough, D. W., Natarajan, J., Vandebosch, A., Rossenu, S., Kramer, M. L., & Eerdekens, M. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283400d58 · Cited by 33
Aktuelle Bewertung neuer/atypischer Neuroleptika
Møller, H. J. (2000) · Der Nervenarzt · doi:10.1007/s001150050567 · Cited by 32
Kolotkin, R. L., Corey‐Lisle, P. K., Crosby, R. D., Kan, H. J., & McQuade, R. D. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.01.1421 · Cited by 31
Yamashita, H., Mori, K., Nagao, M., Okamoto, Y., Morinobu, S., & Yamawaki, S. (2005) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200505000-00006 · Cited by 30
Deberdt, W. G., Lipkovich, I., Heinloth, A. N., Liu, L., Kollack‐Walker, S., Edwards, S., Hoffmann, V. P., & Hardy, T. A. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3153 · Cited by 29
Emsley, R. A., Turner, H. J., Schronen, J., Botha, K., Smit, R., & Oosthuizen, P. P. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005067 · Cited by 28
Deficits in language-mediated mental operations in patients with schizophrenia
Wexler, B. E., Donegan, N. H., Stevens, A. A., & Jacob, S. A. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00194-3 · Cited by 27
Gafoor, R., Landau, S., Craig, T., Elanjithara, T., Power, P., & McGuire, P. K. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181f198da · Cited by 27
Resnick, S. G., Rosenheck, R. A., Cañive, J. M., Souza, C. D., Stroup, T. S., McEvoy, J. P., Thomas, S., Keefe, R. S. E., Swartz, M. S., & Lieberman, J. A. (2008) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-007-9101-3 · Cited by 25
Starting Clozapine in the Community: A UK Perspective
O??Brien, A. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00002 · Cited by 24
Su, T., Malhotra, A. K., Hadd, K., Breier, A., & Pickar, D. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830220102017 · Cited by 21
Antipsychotics - The Future of Schizophrenia Treatment
Beaumont, G. (2000) · Current Medical Research and Opinion · doi:10.1185/0300799009117006 · Cited by 20
PERLICK, D. A., Rosenheck, R. A., Kaczynski, R., Swartz, M. S., Cañive, J. M., & Lieberman, J. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.09.026 · Cited by 19
Rettenbacher, M. A., Hummer, M., Hofer, A., Baumgartner, S., Ebenbichler, C. F., Edlinger, M., Kemmler, G., Lechleitner, M., & Fleischhacker, W. W. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106069467 · Cited by 17
Cited by
Suicide prevention strategies revisited: 10-year systematic review
Zalsman, G., Hawton, K., Wasserman, D., van Heeringen, K., Arensman, E., Sarchiapone, M., Carli, V., Höschl, C., Barzilay, R., Balazs, J., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30030-x · Cited by 1,765
Bang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 675
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Metadata
- Authors
- Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2010-01-20
- Issue
- 1
- Pages
- CD006625-CD006625
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2058181488
- Cited by
- 260
- References
- 223
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.